DUBLIN, August 09, 2021– (BUSINESS WIRE) – The report “CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) – Drugs in Development, 2021” has been added to ResearchAndMarkets.com offer.

CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) – Drugs in Development, 2021 provides an in-depth analysis on the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27).

The report provides comprehensive information with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its comprehensive research and development history, and the latest news and press releases.

In addition, the report provides an overview of the main players involved in the development of targeted therapies against the CD27 antigen and presents dormant and abandoned projects. The report analyzes the pipeline products in relevant therapeutic areas under development targeting the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27).

The report helps to identify and track emerging market players and their portfolios, improves decision-making abilities, and helps to create effective counter-strategies to gain competitive advantage.

Scope

  • The report provides an overview of the global therapeutic landscape for the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27).

  • The report reviews the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) targeted therapies under development by companies and universities / research institutes based on information derived from business and industry. sources.

  • The report covers the pipeline products based on various development stages ranging from pre-registration to discovery and undisclosed stages.

  • The report presents descriptive drug profiles for the products in the pipeline, including a product description, descriptive mechanism of action (MoA), research and development (R&D) brief, licensing and collaboration details and ‘other development activities.

  • The report reviews the main players involved in targeted therapies against the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) and lists all their major and minor projects. .

  • The report assesses targeted therapies against the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) according to the mechanism of action (MoA), pathway of administration (RoA) and type of molecule.

  • The report summarizes all dormant and abandoned pipeline projects.

  • The report reviews the latest news and offers related to the CD27 antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27).

Main topics covered:

  • introduction

  • Cover of the report

  • Target – Overview

  • Target – Therapeutic development

  • Products under development by stage of development

  • Products under development by therapeutic area

  • Products in development by indication

  • Products under development by companies

  • Products under development by universities / institutes

  • Target – Therapeutic evaluation

  • Assessment by mechanism of action

  • Assessment by administration

  • Evaluation by molecule type

  • Target – Companies involved in therapeutic development

  • Target – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

  • Target – Dormant products

  • Target – Discontinued Products

  • Target – Product Development Milestones

  • Featured News & Press Releases

  • Annex

For more information on this report, visit https://www.researchandmarkets.com/r/98iqhd

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210809005263/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Source link